New cell therapy tested for tough blood cancers
NCT ID NCT05895994
Summary
This early-phase study tested a new type of cell therapy called RD13-02 in a small group of patients with aggressive blood cancers that had returned or not responded to standard treatments. The main goals were to check if the treatment was safe and to see how the modified immune cells behaved in the body. Researchers also looked at whether the therapy could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.